Probiotic bacteria Escherichia coli strain Nissle 1917 attenuates acute gastric lesions induced by stress

Journal of Physiology and Pharmacology

Volumn 60, Issue SUPPL.6, 2009, Pages 41-48

  Konturek, Peter C ^a   Sliwowski, Z ^b   Koziel, J ^c   Ptak Belowska, A ^b   Burnat, G ^a   Brzozowski, T ^b   Konturek, S J ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Cyclooxygenase; Cytokines; Escherichia coli strain nissle; Gastric stress lesions; Gastroprotection; Heat shock protein; Probiotics

Indexed keywords

CAPSAICIN; CYCLOOXYGENASE 2; GHRELIN; HEAT SHOCK PROTEIN 70; INDOMETACIN; INTERLEUKIN 1BETA; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBIOTIC AGENT;

ANIMAL; ARTICLE; BIOSYNTHESIS; DISEASE MODEL; DRUG ANTAGONISM; ESCHERICHIA COLI; EXERCISE; IMMERSION; MENTAL STRESS; METABOLISM; PATHOLOGY; RAT; STOMACH MUCOSA; STOMACH ULCER;

ANIMALS; CAPSAICIN; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; GASTRIC MUCOSA; GHRELIN; HSP70 HEAT-SHOCK PROTEINS; IMMERSION; INDOMETHACIN; INTERLEUKIN-1BETA; NITRIC OXIDE SYNTHASE; PPAR GAMMA; PROBIOTICS; RATS; RESTRAINT, PHYSICAL; STOMACH ULCER; STRESS, PSYCHOLOGICAL;

EID: 77954513742     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bohm SK, Kruis W. Probiotics: do they help to control intestinal inflammation? Ann N Y Acad Sci 2006; 1072: 339-350.
2. Mach T. Clinical usefulness of probiotics in inflammatory bowel diseases. J Physiol Pharmacol 2006; 57(Suppl 9): 23-33.
3. Nissle A. Die antagonistische Behandlung chronischer Darmstorungen mit Colibakterien. Med Klin 1918; 2: 29-33.
4. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11(5): 853-858.
5. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53(11): 1617-1623.
6. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25(4): 653-658.
7. Kuzela L, Kascak M, Vavrecka A. Induction and maintenance of remission with nonpathogenic Escherichia coli in patients with pouchitis. Am J Gastroenterol 2001; 96(11): 3218-3219.
8. Tromm A, Niewerth U, Khoury M, et al. The probiotic E. coli strain Nissle 1917 for the treatment of collagenous colitis: first results of an open-label trial. Z Gastroenterol 2004; 42(5): 365-369.
9. Goerg KJ, Schlorer E. Probiotic therapy of pseudomembranous colitis. Combination of intestinal lavage and oral administration of Escherichia coli. Dtsch Med Wochenschr 1998; 123(43): 1274-1278.
10. Krammer HJ, Kamper H, von Bunau R, et al. Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients. Z Gastroenterol 2006; 44(8): 651-656.
11. Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 2003; 15(3): 313-315.
12. Schulze J, Sonnenborn U. 120 Jahre E. coli: Bedeutung in Forschung und Medizin. Hagen: Alfred-Nissle-Gesellschaft e.V. 2006.
13. Gotteland M, Cruchet S, Verbeke S. Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans. Aliment Pharmacol Ther 2001; 15(1): 11-17.
14. Megraud F, Matysiak-Budnik T, Heyman M. Bifidobacterium breve and Streptococcus thermophilus secretion products enhance T helper 1 immune response and intestinal barrier in mice. Exp Biol Med (Maywood) 2005; 230(10): 749-756.
15. Brzozowski T, Zwirska-Korczala K, Konturek PC, et al. Role of circadian rhythm and endogenous melatonin in pathogenesis of acute gastric bleeding erosions induced by stress. J Physiol Pharmacol 2007; 58(Suppl 6): 53-64.
16. Konturek PC, Brzozowski T, Burnat G, et al. Role of braingut axis in healing of gastric ulcers. J Physiol Pharmacol 2004; 55: 179-192.
17. Konturek PC, Brzozowski T, Kania J, et al. Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor gamma, accelerates gastric ulcer healing in rat. Eur J Pharmacol 2003; 472(3): 213-220.
18. Konturek PC, Brzozowski T, Walter B, et al. Ghrelininduced gastroprotection against ischemia-reperfusion injury involves an activation of sensory afferent nerves and hyperemia mediated by nitric oxide. Eur J Pharmacol 2006; 536(1-2): 171-181.
19. Suzuki YJ, Mizuno M, Packer L. Signal transduction for nuclear factor-kappa B activation. Proposed location of antioxidant-inhibitable step. J Immunol 1994; 153(11): 5008-5015.
20. Materia A, Jaffe BM, Money SR, Rossi P, De Marco M, Basso N. Prostaglandins in commercial milk preparations. Their effect in the prevention of stress-induced gastric ulcer. Arch Surg 1984; 119(3): 290-292.
21. Uchida M, Kurakazu K. Yogurt containing Lactobacillus gasseri OLL2716 exerts gastroprotective action against (correction of against) acute gastric lesion and antral ulcer in rats. J Pharmacol Sci 2004; 96(1): 84-90.
22. Brzozowski T, Zwolinska-Wcislo M, Konturek PC, et al. Influence of gastric colonization with Candida albicans on ulcer healing in rats: effect of ranitidine, aspirin and probiotic therapy. Scand J Gastroenterol 2005; 40(3): 286-296.
23. Brzozowski T, Konturek PC, Mierzwa M, et al. Effect of probiotics and triple eradication therapy on the cyclooxygenase (COX)-2 expression, apoptosis and functional gastric mucosal impairment in Helicobacter pylori-infected Mongolian gerbils. Helicobacter 2006; 11(1): 10-20.
24. Zwolinska-Wcislo M, Brzozowski T, Budak A, et al. Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa. J Physiol Pharmacol 2009; 60(1): 107-118.
25. Calatayud S, Barrachina D, Esplugues JV. Nitric oxide: relation to integrity, injury, and healing of the gastric mucosa. Microsc Res Tech 2001; 53(5): 325-335.
26. Konturek PC, Brzozowski T, Pajdo R, et al. Ghrelin-a new gastroprotective factor in gastric mucosa. J Physiol Pharmacol 2004; 55(2): 325-336.
27. Brzozowski T, Konturek PC, Sliwowski Z, et al. Prostaglandin/cyclooxygenase pathway in ghrelin-induced gastroprotection against ischemia-reperfusion injury. J Pharmacol Exp Ther 2006; 319(1): 477-487.
28. Holzer P, Pabst MA. Visceral afferent neurons: role in gastric mucosal protection. News Physiol Sci 1999; 14: 201-206.
29. Rokutan K. Role of heat shock proteins in gastric mucosal protection. J Gastroenterol Hepatol 2000; 15(Suppl): 12-19.
30. Sikora A, Grzesiuk E. Heat shock response in gastrointestinal tract. J Physiol Pharmacol 2007; 58(Suppl 3): 43-62.
31. Hirakawa T, Rokutan K, Nikawa T, Kishi K. Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology 1996; 111(2): 345-357.
32. Ptak-Belowska A, Pawlik MW, Krzysiek-Maczka G, Brzozowski T, Pawlik WW. Transcriptional upregulation of gastrin in response to peroxisome proliferator-activated receptor gamma agonist triggers cell survival pathways. J Physiol Pharmacol 2007; 58(4): 793-801.